{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:56:32Z","timestamp":1791327392215,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,31]]},"DOI":"10.7759\/cureus.91347","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:55:15Z","timestamp":1756670115000},"source":"Crossref","is-referenced-by-count":6,"title":["Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Rubela","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazala S","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishchal","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Muddassar","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumaisa","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elfatih Elamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Jihad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasim","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binish","family":"Essani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.800605","article-title":"Migraine: a review on its history, global epidemiology, risk factors, and comorbidities","volume":"12","author":"Amiri P","year":"2021","unstructured":"Amiri P, Kazeminasab S, Nejadghaderi SA, et al.. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2021, 12:800605. 10.3389\/fneur.2021.800605","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.950","article-title":"What is the actual prevalence of migraine?","volume":"8","author":"Yeh WZ","year":"2018","unstructured":"Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine?. Brain Behav. 2018, 8:e00950. 10.1002\/brb3.950","journal-title":"Brain Behav"},{"key":"ref3","article-title":"Global, regional, and national burden of disorders affecting the nervous system,\r\n1990-2021: a systematic analysis of the Global Burden of Disease Study 2021. [In press]","author":"Steinmetz JD","year":"2021","unstructured":"Steinmetz JD, Seeher K, Schiess N, et al.. Global, regional, and national burden of disorders affecting the nervous system,\r\n1990-2021: a systematic analysis of the Global Burden of Disease Study 2021. [In press]. Lancet Neurol. 2021,","journal-title":"Lancet Neurol"},{"key":"ref4","article-title":"Migraine Headache","author":"Pescador Ruschel MA","year":"2025","unstructured":"Pescador Ruschel MA, De Jesus O. Migraine Headache. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt AK","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, et al.. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021, 17:501-14. 10.1038\/s41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"key":"ref6","article-title":"Preventive treatment","volume":"12","author":"Silberstein SD","year":"2006","unstructured":"Silberstein SD, Young WB. Preventive treatment. Continuum (Minneap Minn). 2006, 12:116-28.","journal-title":"Continuum (Minneap Minn)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp Z","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014, 20:22-33. 10.18553\/jmcp.2014.20.1.22","journal-title":"J Manag Care Pharm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2349791","article-title":"Pharmacological management of migraine: current strategies and future directions","volume":"25","author":"Pellesi L","year":"2024","unstructured":"Pellesi L, Do TP, Hougaard A. Pharmacological management of migraine: current strategies and future directions. Expert Opin Pharmacother. 2024, 25:673-83. 10.1080\/14656566.2024.2349791","journal-title":"Expert Opin Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-024-01745-8","article-title":"Is eptinezumab the key to reducing chronic migraine disability?","volume":"6","author":"Shahid S","year":"2024","unstructured":"Shahid S, Iqbal M. Is eptinezumab the key to reducing chronic migraine disability?. SN Compr Clin Med. 2024, 6:116. 10.1007\/s42399-024-01745-8","journal-title":"SN Compr Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_95_22","article-title":"Advances in CGRP monoclonal antibodies as migraine therapy: a narrative review","volume":"11","author":"Aditya S","year":"2023","unstructured":"Aditya S, Rattan A. Advances in CGRP monoclonal antibodies as migraine therapy: a narrative review. Saudi J Med Med Sci. 2023, 11:11-8. 10.4103\/sjmms.sjmms_95_22","journal-title":"Saudi J Med Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45560","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in preventing migraines: a systematic review","volume":"15","author":"Muddam MR","year":"2023","unstructured":"Muddam MR, Obajeun OA, Abaza A, et al.. Efficacy and safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in preventing migraines: a systematic review. Cureus. 2023, 15:e45560. 10.7759\/cureus.45560","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01128-0","article-title":"Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta-analysis of randomized controlled trials","volume":"18","author":"Yang CP","year":"2021","unstructured":"Yang CP, Zeng BY, Chang CM, Shih PH, Yang CC, Tseng PT, Wang SJ. Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta-analysis of randomized controlled trials. Neurotherapeutics. 2021, 18:2639-50. 10.1007\/s13311-021-01128-0","journal-title":"Neurotherapeutics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01721-6","article-title":"Real-world effectiveness of anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study","volume":"25","author":"Grazzi L","year":"2024","unstructured":"Grazzi L, Giossi R, Montisano DA, Canella M, Marcosano M, Altamura C, Vernieri F. Real-world effectiveness of anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain. 2024, 25:14. 10.1186\/s10194-024-01721-6","journal-title":"J Headache Pain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","article-title":"Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis","volume":"43","author":"Messina R","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023, 43:3331024231152169. 10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications","volume":"39","author":"Dodick DW","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019, 39:445-58. 10.1177\/0333102418821662","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419829007","article-title":"Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials","volume":"39","author":"Xu D","year":"2019","unstructured":"Xu D, Chen D, Zhu LN, Tan G, Wang HJ, Zhang Y, Liu L. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia. 2019, 39:1164-79. 10.1177\/0333102419829007","journal-title":"Cephalalgia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010143","article-title":"Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data","volume":"12","author":"Pavelic AR","year":"2022","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022, 12:143. 10.3390\/cells12010143","journal-title":"Cells"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00716-w","article-title":"Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review","volume":"27","author":"Sevivas H","year":"2022","unstructured":"Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022, 27:86. 10.1186\/s40001-022-00716-w","journal-title":"Eur J Med Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis","volume":"209","author":"Soni P","year":"2021","unstructured":"Soni P, Chawla E. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis. Clin Neurol Neurosurg. 2021, 209:106893. 10.1016\/j.clineuro.2021.106893","journal-title":"Clin Neurol Neurosurg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989601","article-title":"Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis","volume":"41","author":"Drellia K","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia. 2021, 41:851-64. 10.1177\/0333102421989601","journal-title":"Cephalalgia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0464-6","article-title":"Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control","volume":"251","author":"Diener HC","year":"2004","unstructured":"Diener HC, Tfelt-Hansen P, Dahl\u00f6f C, et al.. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004, 251:943-50. 10.1007\/s00415-004-0464-6","journal-title":"J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: a randomized controlled trial","volume":"291","author":"Brandes JL","year":"2004","unstructured":"Brandes JL, Saper JR, Diamond M, et al.. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004, 291:965-73. 10.1001\/jama.291.8.965","journal-title":"JAMA"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313458","article-title":"Randomised clinical trial comparing melatonin 3\u2005mg, amitriptyline 25\u2005mg and placebo for migraine prevention","volume":"87","author":"Gon\u00e7alves AL","year":"2016","unstructured":"Gon\u00e7alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3\u2005mg, amitriptyline 25\u2005mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016, 87:1127-32. 10.1136\/jnnp-2016-313458","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein SD","year":"2007","unstructured":"Silberstein SD, Lipton RB, Dodick DW, et al.. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007, 47:170-80. 10.1111\/j.1526-4610.2006.00684.x","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco S","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019, 20:6. 10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld AM","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, et al.. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013, 53:644-55. 10.1111\/head.12055","journal-title":"Headache"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study","volume":"34","author":"Stovner LJ","year":"2014","unstructured":"Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014, 34:523-32. 10.1177\/0333102413515348","journal-title":"Cephalalgia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies - successful translation from bench to clinic","volume":"14","author":"Edvinsson L","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018, 14:338-50. 10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina M","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al.. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020, 40:241-54. 10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke HC","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018, 91:e2211-21. 10.1212\/WNL.0000000000006640","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399536-patient-adherence-and-long-term-tolerability-of-anti-calcitonin-gene-related-peptide-cgrp-monoclonal-antibodies-in-migraine-prevention-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:55:16Z","timestamp":1756670116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399536-patient-adherence-and-long-term-tolerability-of-anti-calcitonin-gene-related-peptide-cgrp-monoclonal-antibodies-in-migraine-prevention-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.91347","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}